跳至主要内容
临床试验/KCT0008194
KCT0008194招募中未知

ong-term effect of safinamide on motor and non-motor symptoms of Parkinson’s disease

Jeonbuk National University Hospital0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
o Limit 至 o Limit(—)
性别
All

入选标准

  • 1. Diagnosis of Parkinson’s disease according to the United Kingdom Parkinson’s Disease Society Brain Bank criteria.
  • 2. Subjects for whom the decision to initiate Safinamide has been made, according to the judgment of the investigator, who is the neurologist specialized in movement disorder. (The judgement is based on existing evidence and reports on symptoms that have previously reported to be improved by safinamide, which includes the presence of motor fluctuation.)
  • 3. Stable dopaminergic treatment in the last 4 weeks. (Patients already taking other iMAO-B, such as rasagiline or selegiline, were switched to safinamide 50 mg after a 2-week wash-out period)
  • 4. To wish to voluntarily participate and to sign a consent form.

排除标准

  • 1. other disabling concomitant neurological disease (stroke, severe head trauma, neurodegenerative disease, etc.) or other severe and disabling concomitant non-neurological disease (oncological, autoimmune, etc.)
  • 2. incapacity to complete the questionnaires adequately
  • 3. Contraindication to be treated with safinamide according to product data.

研究者

相似试验